EXPERIMENTAL STUDY OF ANTIMICROBIAL PROPERTIES AND ACUTE TOXICITY OF THE PEO-BASED COMBINED SUPPOSITORIES
Abstract
Aim. The research of antimicrobial and toxicological parameters of a promising pharmaceutical composition with indole-3-carbinol and meloxicam in the form of rectal suppositories.
Materials and methods. The research of antimicrobial activity was carried out in vitro by diffusion in nutrient agar in the modification of "holes" on the reference strains of common pathogens Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Bacillus subtilis, Candida albicans.
Adult rats were used for the study of acute toxicity. Suppository mass were administrated in the largest possible volume rectally or orally. The animals were periodically monitored according to the experimental plan – the assessment of physiological parameters before administration and after 6, 12, 18, 24 hours, at 3, 7 and 14 days. The animals were removed from experiment and necropsy provided after 1, 3, 7, and 14 days.
Results. The sizes of zones of inhibition of the microorganisms growth were most significant (from 19.27±0.61 mm of E. coli to 40.80±0.42 mm of S. aureus) near sample of the combined composition suppository compared with other combination of active substances and excipients.
During the observation of animals for 14 days and the study of internal organs after autopsy, deviations in physiological (weight, temperature, activity, respiratory rate) and macroscopic morphological indicators of animals from reference values were not detected.
Conclusion. According to the results of microbiological studies, a moderate antimicrobial effect of suppositories of combined composition in relation to all the studied pathogens was revealed. The absence of manifestations of acute toxicity allows us to conclude that the pharmaceutical composition can be classified as practically non-toxic substances.
The obtained results allow us to recommend a pharmaceutical composition with indole-3-carbinol and meloxicam on a polyethylene oxide basis in the form of suppositories for further preclinical studies of specific pharmacological effects as a prostate protective agent.
Downloads
References
Bradlow, H. L. (2008). Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. In vivo, 22 (4), 441–445.
Nachshon-Kedmi, M., Yannai, S., Haj, A., Fares, F. A. (2003). Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food and Chemical Toxicology, 41 (6), 745–752. doi: http://doi.org/10.1016/s0278-6915(03)00004-8
Chinni, S. R., Li, Y., Upadhyay, S., Koppolu, P. K., Sarkar, F. H. (2001). Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene, 20 (23), 2927–2936. doi: http://doi.org/10.1038/sj.onc.1204365
Chinni, S. R., Sarkar, F. H. (2002). Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clinical cancer research, 8 (4), 1228–1236.
Hsu, J. C., Zhang, J., Dev, A., Wing, A., Bjeldanes, L. F., Firestone, G. L. (2005). Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis, 26 (11), 1896–1904. doi: http://doi.org/10.1093/carcin/bgi155
Reddy, G. P. V., Barrack, E. R., Dou, Q. P., Menon, M., Pelley, R., Sarkar, F. H., Sheng, S. (2006). Regulatory processes affecting androgen receptor expression, stability, and function: Potential targets to treat hormone-refractory prostate cancer. Journal of Cellular Biochemistry, 98 (6), 1408–1423. doi: http://doi.org/10.1002/jcb.20927
Sung, W. S., Lee, D. G. (2007). In Vitro Antimicrobial Activity and the Mode of Action of Indole-3-Carbinol against Human Pathogenic Microorganisms. Biological & Pharmaceutical Bulletin, 30 (10), 1865–1869. doi: http://doi.org/10.1248/bpb.30.1865
Ishiguro, H., Kawahara, T. (2014). Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases. BioMed Research International, 2014, 1–6. doi: http://doi.org/10.1155/2014/436123
Canale, D., Scaricabarozzi, I., Giorgi, P., Turchi, P., Ducci, M., Menchini-Fabris, G. F. (2009). Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis. Andrologia, 25 (3), 163–166. doi: http://doi.org/10.1111/j.1439-0272.1993.tb02701.x
Wang, W., Bergh, A., Damber, J.-E. (2004). Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. The Prostate, 61 (1), 60–72. doi: http://doi.org/10.1002/pros.20061
Disilverio, F., Bosman, C., Salvatori, M., Albanesi, L., Proiettipannunzi, L., Ciccariello, M. et. al. (2005). Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). European Urology, 47 (1), 72–79. doi: http://doi.org/10.1016/j.eururo.2004.08.024
Minnery, C. H., Getzenberg, R. H. (2005). benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and ibuprofen. Journal of Urology, 174 (1), 375–379. doi: http://doi.org/10.1097/01.ju.0000161598.24740.34
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B. et. al. (2000). Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal of Medicine, 343 (21), 1520–1528. doi: http://doi.org/10.1056/nejm200011233432103
Boehringer Ingelheim Pharmaceuticals. Mobic (meloxicam) tablets prescribing information (2006). Ridgefield, 10.
Choi, C. H., Moon, Y. S., Han, J. H., Lee, K. I., Kim, H. J. (2015). Pat. No. 14/414,883 USA. Composition comprising dendropanax morbiferaextract or compound derived therefrom as active ingredient for preventing and treating benign prostatic hyperplasia.
Carrabba, M., Paresce, E., Angelini, M., Galanti, A., Marini, M. G., Cigarini, P. (1995). A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Current Medical Research and Opinion, 13 (6), 343–355. doi: http://doi.org/10.1185/03007999509110494
Ravshanov, T. B., Zaychenko, G. V., Zaychenko, V. S., Ruban, O. A. (2018). Farmakologіchne doslіdzhennya supozitorіiv dlya lіkuvannya dobroyakіsnih zahvoryuvan peredmіhurovoi zalozi. Web of Scholar, 1 (8 (26)), 51–57.
Stefanov, O. V. (2001). Doklіnіchnі doslіdzhennya lіkarskih zasobіv. Kiiv: Avіcena, 292–306.
Pharmacopoeia B. (2016). British pharmacopoeia.
European Pharmacopoeia Commission. European pharmacopoeia. Vol. 2. Maisonneuve.
U. S. Pharmacopeia. National Formulary USP 38 – NF 33. Rockville: The United States Pharmacopeial Convention. Available at: https://www.uspnf.com/official-text/proposal-statuscommentary/usp-38-nf-33
Volianskyi, Yu. L., Hrytsenko, I. S., Shyrobokov, V. P. (2004). Vyvchennia spetsyfichnoi aktyvnosti protymikrobnykh likarskykh zasobiv. Kyiv: Zdorovia, 38.
Khabriev, R. U., Verstakova, O. L., Arzamascev, E. V., Babaian, E. A., Belousov, Iu. B. et. al. (2005). Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniiu novykh farmakologicheskikh veschestv. Otkrytoe akcionernoe obschestvo Izdatelstvo Medicina, 832.
Dacenko, B. M., Biriukova, S. V., Tamm, T. I. (1989). Metodicheskie rekomendacii po eksperimentalnomu (doklinicheskomu) izucheniiu lekarstvennykh preparatov dlia mestnogo lecheniia gnoinykh ran. Moscow, 45.
Semina, N. A., Sidorenko, S. V., Rezvan, S. P., Grudinina, S. A., Strachunskii, L. S. et. al. (2004). Opredelenie chuvstvitelnosti mikroorganizmov k antibakterialnym preparatam. MUK 4.2.1890-04. Moscow: Federalnii Centr Gossanepidnazora Minzdrava Rossii, 91.
Yevropeiska konventsiia pro zakhyst khrebetnykh tvaryn vid 1986 r. Available at: http://zakon5.rada.gov.ua/laws/show/994_137
Pro zakhyst tvaryn vid zhorstokoho povodzhennia (2006). Zakon Ukrainy No. 3447-IV. 21.02.2006. Vidomosti Verkhovnoi Rady Ukrainy, 27, 230.
Larianovska, Yu. B., Kotelevets, N. V. (2005). Morfostruktura peredmikhurovoi zalozy bilykh laboratornykh shchuriv. Medytsyna sehodnia y zavtra, 1, 12–14.
Glanc, S. (1999). Mediko-biologicheskaia statistika. Moscow: Praktika, 459.
Fiziologicheskie, biokhimicheskie i biometricheskie pokazateli normy eksperimentalnykh zhivotnykh (2013). Saint Petersburg: Izd-vo «LEMA», 116.
Meloksykam. Informatsiinyi fond «Derzhavnyi reiestr likarskykh zasobiv Ukrainy». MOZ Ukrainy. Available at: http://drlz.com.ua/
Shertzer, H. G., Sainsbury, M. (1991). Intrinsic acute toxicity and hepatic enzyme inducing properties of the chemoprotectants indole-3-carbinol and 5,10-dihydroindeno[1,2-b]indole in mice. Food and Chemical Toxicology, 29 (4), 237–242. doi: http://doi.org/10.1016/0278-6915(91)90020-8
Lehmann, H. A., Baumeister, M., Lützen, L., Wiegleb, J. (1996). Meloxicam: A toxicology overview. Inflammopharmacology, 4 (2), 105–123. doi: http://doi.org/10.1007/bf02735465
Nathan, A., Zalipsky, S., Ertel, S. I., Agathos, S. N., Yarmush, M. L., Kohn, J. (1993). Copolymers of lysine and polyethylene glycol: a new family of functionalized drug carriers. Bioconjugate Chemistry, 4 (1), 54–62. doi: http://doi.org/10.1021/bc00019a008
Copyright (c) 2019 Tymur Ravshanov, Ganna Zaychenko, Kateryna Zhemerova, Volodymyr Zaychenko, Olena Ruban
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.